Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response to Cancer Immunotherapy

Chronix Biomedical

First study of a liquid biopsy to predict response to immunotherapy...

By | March 20th, 2017|Chronix news|0 Comments

Chronix Biomedical provides update on studies and presentations

Chronix Biomedical

Data from pilot studies using Chronix’s CNI test submitted for presentation at a high profile scientific meeting...

By | February 27th, 2017|Chronix news|0 Comments

Advanced Cancer Diagnostics Showcasingat 2016 NCRI Cancer Conference 6-9 November 2016

Chronix Biomedical’s Ireland & UK distributors Advanced Cancer Diagnostics will be attending and showcasing the latest Chronix diagnostic tests: Second Opinion Prostate Cancer Evaluation Test Second Opinion Breast Cancer Evaluation Test Delta Dot Treatment Monitoring Test CNI Cancer Evaluation Test Please visit our booth #79 at The BT Convention Centre, Kings Dock, Waterfront, Liverpool L3 [...]

By | November 3rd, 2016|Events|0 Comments

ASCO 2016

“Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2” , was presented at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting 2016 on 5 June 2016 at McCormick Place in Chicago, Illinois. The abstract and poster presentation describe the work conducted by independent oncologists in a blinded [...]

By | November 3rd, 2016|Events|0 Comments

Chronix Biomedical updates on progress with prostate and pancreatic cancer validation studies

Chronix Biomedical

Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, is pleased to update investors on the progress of two clinical studies...

By | November 3rd, 2016|Chronix news|0 Comments

Experts from Chronix Biomedical about the CNI Tests – Innovative Cancer Diagnostics

#TheTurningPointInCancerFight

By | November 3rd, 2016|Video|0 Comments

Prof. Piotr Radziszewski – New generation oncological biomarkers – focusing on Chronix company

Prof. Piotr Radziszewski. New generation oncological biomarkers – focusing on Chronix company. 1.10.2016.

We present a lecture delivered at the 5th Polish women and men health debate according to Medical guidelines – kidney cancer, bladder cancer.

By | November 3rd, 2016|Medical publications, Video|0 Comments

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor cell-free DNA copy number instability (CNI) to predict therapeutic response to immunotherapy prior to cycle 2. J ClinOncol 34, 2016 (suppl; abstr 3027).

We measured CNAs changes during treatment by computing a genomic copy number instability index (CNI) of cfDNA and Treg-specific demethylation region (TSDR) as measure for Tregs% of leukocytes compared to response.

By | November 3rd, 2016|Medical publications|0 Comments

Predicting Treatment Outcomes in Chemotherapy

Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.

Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

By | November 3rd, 2016|Medical publications|0 Comments

Prostate Cancer Blood Test

Schütz, E., et al. Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer. Clinical Chemistry 2015; 61: 239-248.

Tumor-specific cell free DNA (cfDNA) present in serum and plasma provides a real-time, easily accessible surrogate. We demonstrated variations in the number of cfDNA sequences circulating in the serum of patients with prostate cancer compared with healthy controls.

By | November 3rd, 2016|Medical publications|0 Comments